NYSE:EWMedical Equipment
Edwards Lifesciences (EW) Q1 Net Margin Compression Tests Bullish Growth Narratives
Edwards Lifesciences (EW) opened 2026 with Q1 revenue of US$1,648.6 million and basic EPS of US$0.66, setting the tone for how its earnings story is evolving off a higher revenue base and solid per share profit. Over the past five quarters, revenue has moved from US$1,385.8 million in Q4 2024 to US$1,412.7 million in Q1 2025 and US$1,648.6 million in the latest quarter, while quarterly basic EPS has ranged from US$0.11 in Q4 2025 to US$0.66 in Q1 2026. This gives investors a clearer view of...